A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19.
Fowotade A, Bamidele F, Egbetola B, Fagbamigbe AF, Adeagbo BA, Adefuye BO, Olagunoye A, Ojo TO, Adebiyi AO, Olagunju OI, Ladipo OT, Akinloye A, Onayade A, Bolaji OO, Rannard S, Happi C, Owen A, Olagunju A.
Fowotade A, et al. Among authors: ladipo ot.
Front Med (Lausanne). 2022 Sep 8;9:956123. doi: 10.3389/fmed.2022.956123. eCollection 2022.
Front Med (Lausanne). 2022.
PMID: 36160134
Free PMC article.